JO
CLYM

John Overdeck’s Climb Bio CLYM Stock Holding History

John Overdeck’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Sell
148,238
-162,368
-52% -$1.68M ﹤0.01% 3025
2026
Q1 		$2.13M Sell
310,606
-256,106
-45% -$1.48M ﹤0.01% 2711
2025
Q4 		$2.27M Buy
566,712
+454,031
+403% +$1.09M ﹤0.01% 2345
2025
Q3 		$226K Sell
112,681
-66,910
-37% -$124K ﹤0.01% 3335
2025
Q2 		$223K Sell
179,591
-75,523
-30% -$94K ﹤0.01% 2880
2025
Q1 		$311K Buy
255,114
+17,404
+7% +$28.2K ﹤0.01% 2701
2024
Q4 		$428K Buy
237,710
+214,196
+911% +$775K ﹤0.01% 2599
2024
Q3 		$120K Buy
+23,514
New +$166K ﹤0.01% 2877

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

John Overdeck's CLYM Position: Q2 2026 in Review

John Overdeck reduced its Climb Bio (CLYM) stake by 52% in Q2 2026, selling an estimated $1.68M and leaving 148,238 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #3025.

John Overdeck first reported a position in CLYM in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.27M in Q4 2025. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • John Overdeck held 148,238 shares of Climb Bio worth $1.93M as of Q2 2026.
  • John Overdeck sold 162,368 Climb Bio shares in Q2 2026, an estimated $1.68M.
  • Climb Bio made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3025 holding.
  • John Overdeck first reported a position in Climb Bio in Q3 2024 and has held it in 8 quarters since.
  • John Overdeck's Climb Bio position peaked at $2.27M in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.